Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Sangeun, Ko, Meehyun, Lee, Jihye, Choi, Inhee, Byun, Soo Young, Park, Soonju, Shum, David, Kim, Seungtaek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318052/
https://www.ncbi.nlm.nih.gov/pubmed/32366720
http://dx.doi.org/10.1128/AAC.00819-20
Descripción
Sumario:Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC(50)s), and in particular, two FDA-approved drugs—niclosamide and ciclesonide—were notable in some respects.

Ejemplares similares